Article
Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study
Registration in:
PEREIRA, Evelyn Nunes Goulart da Silva et al. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World Journal of Gastroenterology, v. 27, n. 29, p. 4913-4928, Aug. 2021.
1007-9327
10.3748/wjg.v27.i29.4913
2219-2840
Author
Pereira, Evelyn Nunes Goulart da Silva
Paula, Daniela Polessa
Araujo, Beatriz Peres de
Fonseca, Maria de Jesus Mendes da
Diniz, Maria de Fátima Haueisen Sander
Daliry, Anissa
Griep, Rosane Harter
Abstract
BACKGROUND
Liver diseases are associated with the excess formation of advanced glycation end
products (AGEs), which induce tissue inflammation and oxidative damage.
However, the trend of oxidative marker levels according to the steatosis grade in
non-alcoholic fatty liver disease (NAFLD) is unclear.
AIM
To compare serum AGE levels between participants with NAFLD accordingly to
steatosis severity in the baseline ELSA-Brasil population.
METHODS
In 305 individuals at baseline ELSA-Brasil, NAFLD-associated steatosis was
classified by ultrasound hepatic attenuation. The participants were grouped
according to the severity of steatosis: mild and moderate/severe pooled. The
measurement of serum fluorescent AGE concentrations was based on spectro fluorimetric detection. Serum AGE content and clinical and laboratory character istics of the participants were compared between groups. The correlation between serum AGE levels and the grade of steatosis was analyzed. Logistic regression
analysis was used to investigate the relationship between serum AGE levels and
steatosis severity. A P value < 0.05 was considered statistically significant.